These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12585231)

  • 21. Drug evaluation, drug development and pharmacogenetics: celebrating 30 years of progress.
    Li Wan Po A
    J Clin Pharm Ther; 2005 Feb; 30(1):1-4. PubMed ID: 15658998
    [No Abstract]   [Full Text] [Related]  

  • 22. The future of drug safety testing: expanding the view and narrowing the focus.
    Stevens JL; Baker TK
    Drug Discov Today; 2009 Feb; 14(3-4):162-7. PubMed ID: 19100337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative structure-pharmacokinetic/pharmacodynamic relationships.
    Mager DE
    Adv Drug Deliv Rev; 2006 Nov; 58(12-13):1326-56. PubMed ID: 17092600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Computer EEG drug data base in psychopharmacology and in drug development.
    Itil TM; Menon GN; Itil KZ
    Psychopharmacol Bull; 1982 Oct; 18(4):165-72. PubMed ID: 7156284
    [No Abstract]   [Full Text] [Related]  

  • 25. Preclinical and clinical development of immunocytokines.
    Sondel PM; Hank JA; Gan J; Neal Z; Albertini MR
    Curr Opin Investig Drugs; 2003 Jun; 4(6):696-700. PubMed ID: 12901228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New strategies to address drug-drug interactions involving OATPs.
    Poirier A; Funk C; Lavé T; Noé J
    Curr Opin Drug Discov Devel; 2007 Jan; 10(1):74-83. PubMed ID: 17265745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Backup programs in drug discovery.
    Greenlee WJ; Desai M
    Curr Opin Drug Discov Devel; 2006 Jul; 9(4):412-3. PubMed ID: 16889224
    [No Abstract]   [Full Text] [Related]  

  • 28. Hit and Lead identification: efficient practices for drug discovery.
    Goodnow RA; Gillespie P
    Prog Med Chem; 2007; 45():1-61. PubMed ID: 17280901
    [No Abstract]   [Full Text] [Related]  

  • 29. Advances in multivariate analysis in pharmaceutical process development.
    McKay B; Hoogenraad M; Damen EW; Smith AA
    Curr Opin Drug Discov Devel; 2003 Nov; 6(6):966-77. PubMed ID: 14758764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.
    Danhof M; de Lange EC; Della Pasqua OE; Ploeger BA; Voskuyl RA
    Trends Pharmacol Sci; 2008 Apr; 29(4):186-91. PubMed ID: 18353445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of drugs that interact with herbs in drug development.
    Zhou SF; Zhou ZW; Li CG; Chen X; Yu X; Xue CC; Herington A
    Drug Discov Today; 2007 Aug; 12(15-16):664-73. PubMed ID: 17706549
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Animal pharmaco-EEG: models, facts and fallacies.
    Ruigt GS
    Methods Find Exp Clin Pharmacol; 2002; 24 Suppl D():59-61. PubMed ID: 12575469
    [No Abstract]   [Full Text] [Related]  

  • 33. A review of high throughput technology for the screening of natural products.
    Mishra KP; Ganju L; Sairam M; Banerjee PK; Sawhney RC
    Biomed Pharmacother; 2008 Feb; 62(2):94-8. PubMed ID: 17692498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. All systems go?
    Watson C
    Drug Discov Today; 2004 Dec; 9(24):1040-2. PubMed ID: 15582791
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacodynamic modeling of anesthetic EEG drug effects.
    Stanski DR
    Annu Rev Pharmacol Toxicol; 1992; 32():423-47. PubMed ID: 1605573
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacokinetic-pharmacodynamic modeling the hypnotic effect of sevoflurane using the spectral entropy of the electroencephalogram.
    McKay ID; Voss LJ; Sleigh JW; Barnard JP; Johannsen EK
    Anesth Analg; 2006 Jan; 102(1):91-7. PubMed ID: 16368811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and pharmacodynamics of intravenously administered anesthetic drugs: concepts and lessons for drug development.
    Kern SE; Stanski DR
    Clin Pharmacol Ther; 2008 Jul; 84(1):153-7. PubMed ID: 18463623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Application of novel quantitative bioanalytical methods for pharmacokinetic and pharmacokinetic/pharmacodynamic assessments of antisense oligonucleotides.
    Yu RZ; Geary RS; Levin AA
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):195-203. PubMed ID: 15603253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mathematical modeling of drug delivery.
    Siepmann J; Siepmann F
    Int J Pharm; 2008 Dec; 364(2):328-43. PubMed ID: 18822362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of experimental strategies for the development of chiral chromatographic methods based on diastereomer formation.
    Srinivas NR
    Biomed Chromatogr; 2004 May; 18(4):207-33. PubMed ID: 15162384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.